Explanation_NOMZ
of_PIN
transition_NOMZ
to_PIN
IFRS_NN
137_CD
EXPLANATION_NOMZ
OF_PIN
TRANSITION_NOMZ
TO_PIN
IFRS_NN
These_DEMP
are_VPRT [BEMA]
the_DT
Groups_NN
first_RB
consolidated_JJ
financial_JJ
statements_NOMZ
prepared_VBN [WZPAST]
in_PIN
accordance_NN
with_PIN
IFRS_NN
._.
The_DT
accounting_GER
policies_NN
set_VBN [WZPAST]
out_PIN
on_PIN
pages_NN
87_CD
to_PIN
89_CD
have_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
in_PIN
preparing_VBG
the_DT
Financial_NN
Statements_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2005_CD
,_,
the_DT
comparative_JJ
information_NOMZ
presented_VBN [WZPAST]
in_PIN
these_DEMO
financial_JJ
statements_NOMZ
for_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
2004_CD
and_CC
31_CD
December_NN
2003_CD
and_CC
in_PIN
the_DT
preparation_NOMZ
of_PIN
an_DT
opening_GER
IFRS_NN
balance_NN
sheet_NN
at_PIN
1_CD
January_NN
2003_CD
the_DT
Groups_NN
date_NN
of_PIN
transition_NOMZ
._.
In_PIN
preparing_VBG
its_PIT
opening_GER
balance_NN
sheet_NN
,_,
the_DT
Group_NN
has_VPRT [PEAS]
adjusted_VBN
amounts_NN
reported_VBD [PUBV]
previously_TIME
in_PIN
Financial_NN
Statements_NOMZ
prepared_VBD
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
._.
An_DT
explanation_NOMZ
of_PIN
how_RB
the_DT
transition_NOMZ
from_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
has_VPRT [PEAS]
affected_VBN
the_DT
Groups_NN
financial_JJ
position_NOMZ
,_,
financial_JJ
performance_NN
and_PHC
cash_NN
flows_NN
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
following_VBG
tables_NN
and_CC
the_DT
notes_NN
that_TSUB
accompany_VPRT
the_DT
tables_NN
._.
The_DT
information_NOMZ
below_PLACE
differs_VPRT
from_PIN
that_DEMP
presented_VBN
in_PIN
January_NN
2005_CD
in_PIN
the_DT
2004_CD
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
Information_NOMZ
in_PIN
that_DEMO
certain_JJ
income_NN
statement_NOMZ
and_PHC
balance_NN
sheet_NN
items_NN
have_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
._.
In_CONJ
addition_NULL
,_,
as_IN
noted_VBN [PRIV]
in_PIN
the_DT
accounting_GER
policies_NN
on_PIN
page_NN
88_CD
,_,
the_DT
comparative_JJ
information_NOMZ
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
restated_VBN
to_TO
reflect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
IAS_NN
39_CD
,_,
Financial_NN
Instruments_NOMZ
:_:
Recognition_NOMZ
and_PHC
Measurement_NOMZ
the_DT
Fair_NN
Value_NN
Option_NOMZ
._.
31_CD
Dec_NN
2004_CD
1_CD
Jan_NN
2003_CD
Total_JJ
equity_NOMZ
$_$
m_CD
$_$
m_CD [BEMA]
Total_JJ
equity_NOMZ
under_IN
UK_NN
GAAP_NN
14,519_CD
11,226_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
IFRS_NN
Employee_NN
benefits_NN
2,010_CD
1,380_CD
Financial_NN
instruments_NOMZ
11_CD
153_CD
Share-based_JJ
payments_NOMZ
Goodwill_NN
108_CD
Dividends_NN
1,061_CD
808_CD
Capitalised_VBN
software_NN
and_CC
other_JJ
intangibles_NN
106_CD
80_CD
Other_JJ
12_CD
1_CD
Deferred_JJ
tax_NN
IFRS_NN
adjustments_NOMZ
above_PLACE
579_CD
362_CD
other_JJ
111_CD
82_CD
Total_JJ
equity_NOMZ
under_IN
IFRS_NN
14,497_CD
11,168_CD
Year_NN
ended_VBD
31_CD
Dec_NN
2004_CD
Profit_NN
for_PIN
the_DT
period_NN
$_$
m_CD
Profit_NN
for_PIN
the_DT
period_NN
under_IN
UK_NN
GAAP_NN
3,831_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
IFRS_NN
Employee_NN
benefits_NN
1_CD
Financial_NN
instruments_NOMZ
163_CD
Share-based_JJ
payments_NOMZ
147_CD
Goodwill_NN
49_CD
Capitalised_NN
software_NN
and_CC
other_JJ
intangibles_NN
21_CD
Other_JJ
2_CD
Deferred_JJ
tax_NN
IFRS_NN
adjustments_NOMZ
above_PLACE
26_CD
other_JJ
67_CD
Profit_NN
for_PIN
the_DT
period_NN
under_IN
IFRS_NN
3,683_CD
Under_IN
IAS_NN
7_CD
Cash_NN
Flow_NN
Statements_NOMZ
,_,
movements_NOMZ
on_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
are_VPRT [PASS]
reconciled_VBN
:_:
under_IN
UK_NN
GAAP_NN
the_DT
statement_NOMZ
reconciles_VPRT
cash_NN
only_DWNT
._.
The_DT
change_NN
in_PIN
the_DT
presentation_NOMZ
of_PIN
the_DT
cash_NN
flow_NN
statement_NOMZ
under_IN
IAS_NN
7_CD
makes_VPRT
no_SYNE
difference_NN
to_PIN
the_DT
free_JJ
cash_NN
generated_VBN [WZPAST]
by_PIN
the_DT
Group_NN
._.
IFRS_NN
TRANSITIONAL_NN
ARRANGEMENTS_NOMZ
AND_PHC
EARLY_TIME
ADOPTION_NOMZ
When_RB
preparing_VBG
the_DT
consolidated_JJ
balance_NN
sheet_NN
under_IN
IFRS_NN
at_PIN
1_CD
January_NN
2003_CD
,_,
the_DT
date_NN
of_PIN
transition_NOMZ
,_,
the_DT
following_VBG
optional_JJ
exemptions_NOMZ
from_PIN
full_JJ
retrospective_JJ
application_NOMZ
of_PIN
IFRS_NN
accounting_GER
policies_NN
have_VPRT [PEAS]
been_VBN [PASS]
adopted_VBN
:_:
Business_NOMZ
combinations_NOMZ
the_DT
provisions_NN
of_PIN
IFRS_NN
3_CD
have_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
prospectively_RB
from_PIN
1_CD
January_NN
2003_CD
._.
Business_NOMZ
combinations_NOMZ
that_TSUB
occurred_VBD
before_IN
1_CD
January_NN
2003_CD
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
restated_VBN
._.
Employee_NN
benefits_NN
the_DT
accumulated_VBN
actuarial_JJ
gains_NN
and_PHC
losses_NN
in_PIN
respect_NN
of_PIN
employee_NN
defined_VBN
benefit_NN
plans_NN
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
full_JJ
through_PIN
reserves_NN
at_PIN
1_CD
January_NN
2003_CD
._.
Cumulative_JJ
exchange_NN
differences_NN
cumulative_JJ
translation_NOMZ
differences_NN
on_PIN
net_JJ
investments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
set_VBN
to_TO
zero_VB
at_PIN
1_CD
January_NN
2003_CD
._.
The_DT
following_VBG
optional_JJ
exemptions_NOMZ
from_PIN
full_JJ
retrospective_JJ
application_NOMZ
of_PIN
IFRS_NN
accounting_GER
policies_NN
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
adopted_VBN
:_:
Fair_NN
value_NN
or_CC
revaluation_NOMZ
an_DT
entity_NOMZ
may_POMD
elect_VB
to_TO
use_VB
fair_JJ
value_NN
or_CC
a_DT
previous_JJ
GAAP_NN
revaluation_NOMZ
at_PIN
the_DT
opening_GER
balance_NN
sheet_NN
date_NN
._.
This_DEMO
exemption_NOMZ
did_VBD
not_XX0
apply_VB
to_PIN
AstraZeneca_NN
._.
Compound_NN
financial_JJ
instruments_NOMZ
If_COND
the_DT
compound_NN
financial_JJ
instruments_NOMZ
are_VPRT
no_RB
longer_RB
outstanding_JJ
at_PIN
the_DT
date_NN
of_PIN
transition_NOMZ
,_,
then_RB
the_DT
entity_NOMZ
is_VPRT [PASS]
not_XX0
required_VBN [SUAV]
to_TO
split_VB
the_DT
instrument_NOMZ
into_PIN
the_DT
separate_JJ
equity_NOMZ
and_PHC
liability_NOMZ
components_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
138_CD
Form_NN
20-F_JJ
Information_NOMZ
2005_CD
EXPLANATION_NOMZ
OF_PIN
TRANSITION_NOMZ
TO_PIN
IFRS_NN
CONTINUED_VBD
IFRS_NN
TRANSITIONAL_JJ
ARRANGEMENTS_NOMZ
AND_PHC
EARLY_TIME
ADOPTION_NOMZ
CONTINUED_VBD
In_CONJ
addition_NULL
the_DT
Group_NN
has_VPRT [PEAS]
chosen_VBN
to_TO
restate_VB
comparative_JJ
information_NOMZ
with_PIN
respect_NN
to_PIN
IAS_NN
32_CD
Financial_NN
Instruments_NOMZ
:_:
Disclosure_NN
and_PHC
Presentation_NOMZ
and_PHC
IAS_NN
39_CD
Financial_NN
Instruments_NOMZ
:_:
Recognition_NOMZ
and_PHC
Measurement_NOMZ
._.
IFRS_NN
2_CD
Share-based_JJ
Payments_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
adopted_VBN
with_PIN
full_JJ
retrospective_JJ
application_NOMZ
._.
The_DT
Group_NN
has_VPRT [SPAU] [PEAS]
also_RB
adopted_VBN
the_DT
amendment_NOMZ
to_PIN
IAS_NN
19_CD
Employee_NN
Benefits_NN
early_TIME
,_,
allowing_VBG [SUAV]
actuarial_JJ
gains_NN
or_CC
losses_NN
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
directly_RB
in_PIN
the_DT
consolidated_JJ
statement_NOMZ
of_PIN
income_NN
and_PHC
expense_NN
in_PIN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
arise_VPRT
._.
Comparative_JJ
information_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
on_PIN
this_DEMO
basis_NN
._.
OTHER_JJ
RECLASSIFICATIONS_NOMZ
Phase_NN
4_CD
post-launch_JJ
trial_NN
costs_NN
of_PIN
$_$
388m_CD
in_PIN
2004_CD
were_VBD [PASS]
reclassified_VBN
to_TO
selling_VBG
,_,
general_JJ
and_PHC
administrative_JJ
costs_NN
from_PIN
research_NN
and_PHC
development_NOMZ
as_IN
part_NN
of_PIN
the_DT
transition_NOMZ
to_PIN
IFRS_NN
._.
This_DEMP
is_VPRT [PASS]
not_XX0
shown_VBN [PRIV]
in_PIN
the_DT
above_PLACE
reconciliations_NOMZ
as_IN
there_EX
was_VBD
no_SYNE
profit_NN
or_CC
equity_NOMZ
impact_NN
._.
EFFECTS_NN
OF_PIN
IFRS_NN
IN_PIN
FINANCIAL_NN
STATEMENTS_NOMZ
Employee_NN
benefits_NN
IAS_NN
19_CD
requires_VPRT [SUAV]
deficits_NN
and_PHC
surpluses_NN
in_PIN
company_NN
pension_NN
schemes_NN
to_TO
be_VB [PASS]
recorded_VBN
on_PIN
the_DT
balance_NN
sheet_NN
._.
IAS_NN
19_CD
also_RB
requires_VPRT [SUAV]
separate_JJ
recognition_NOMZ
of_PIN
the_DT
operating_GER
and_PHC
financing_GER
costs_NN
of_PIN
defined_VBN
benefit_NN
pensions_NN
and_CC
other_JJ
post-retirement_JJ
employee_NN
benefits_NN
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Actuarial_JJ
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
full_JJ
immediately_TIME
in_PIN
the_DT
statement_NOMZ
of_PIN
recognized_VBN [PRIV]
income_NN
and_PHC
expense_NN
and_CC
cumulative_JJ
actuarial_JJ
gains_NN
and_PHC
losses_NN
at_PIN
1_CD
January_NN
2003_CD
have_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
full_JJ
as_IN
an_DT
adjustment_NOMZ
to_TO
opening_VBG
retained_VBN
earnings_GER
._.
Financial_NN
instruments_NOMZ
IAS_NN
32_CD
sets_VPRT
out_PIN
the_DT
presentation_NOMZ
and_PHC
disclosure_NN
requirements_NOMZ
in_PIN
respect_NN
of_PIN
financial_JJ
instruments_NOMZ
,_,
whilst_OSUB
IAS_NN
39_CD
stipulates_VPRT [SUAV]
the_DT
measurement_NOMZ
and_PHC
recognition_NOMZ
requirements_NOMZ
._.
The_DT
general_JJ
principle_NN
of_PIN
IAS_NN
39_CD
is_VPRT
that_DEMO
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
should_NEMD
be_VB [PASS]
recognized_VBN [PRIV]
at_PIN
fair_JJ
value_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
opted_VBN
to_TO
apply_VB
the_DT
financial_JJ
instruments_NOMZ
standards_NN
,_,
IAS_NN
32_CD
and_CC
IAS_NN
39_CD
,_,
retrospectively_RB
in_PIN
order_NN
to_TO
give_VB
a_DT
more_EMPH
meaningful_JJ
view_NN
of_PIN
the_DT
Groups_NN
results_NN
and_CC
financial_JJ
position_NOMZ
._.
Accounting_GER
for_PIN
the_DT
movements_NOMZ
in_PIN
fair_JJ
value_NN
is_VPRT [BEMA]
dependent_PRED
on_PIN
the_DT
designation_NOMZ
of_PIN
the_DT
relevant_JJ
financial_JJ
instrument_NOMZ
,_,
with_PIN
movements_NOMZ
going_VBG [WZPRES]
through_PIN
either_CC
the_DT
income_NN
statement_NOMZ
and_CC
or_CC
being_VBG [PASS]
taken_VBN
directly_RB
to_PIN
equity_NOMZ
._.
Share-based_JJ
payments_NOMZ
IFRS_VPRT
2_CD
requires_VPRT [SUAV]
that_THVC
a_DT
charge_NN
is_VPRT [PASS]
recorded_VBN
in_PIN
respect_NN
of_PIN
shares_NN
and_PHC
share_NN
options_NOMZ
that_TSUB
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
recognized_VBN [PRIV]
a_DT
charge_NN
to_PIN
income_NN
representing_VBG [WZPRES]
the_DT
fair_JJ
value_NN
of_PIN
outstanding_JJ
employee_NN
share_NN
options_NOMZ
granted_VBN [SUAV]
to_TO
approximately_RB
9,000_CD
employees_NN
and_CC
has_VPRT [PEAS]
followed_VBN
the_DT
optional_JJ
transitional_JJ
arrangements_NOMZ
which_WDT [WHSUB]
allow_VPRT [SUAV]
companies_NN
that_TSUB
have_VPRT [SPAU] [PEAS]
previously_TIME
disclosed_VBN [PUBV]
the_DT
fair_JJ
value_NN
charge_NN
,_,
to_TO
apply_VB
IFRS_NN
2_CD
fully_AMP
retrospectively_RB
to_PIN
all_QUAN
options_NOMZ
granted_VBN [SUAV]
but_CC
not_XX0
fully_AMP
vested_VBN
at_PIN
the_DT
relevant_JJ
reporting_GER
date_NN
._.
This_DEMO
approach_NN
is_VPRT [PASS]
encouraged_VBN
in_PIN
the_DT
standard_NN
and_CC
gives_VPRT
a_DT
better_JJ
indication_NOMZ
of_PIN
how_RB
past_JJ
results_NN
are_VPRT [BYPA]
affected_VBN
by_PIN
IFRS_NN
2_CD
._.
Business_NOMZ
combinations_NOMZ
IFRS_VPRT
3_CD
prohibits_VPRT
merger_NN
accounting_GER
and_CC
the_DT
amortisation_NOMZ
of_PIN
goodwill_NN
._.
The_DT
standard_JJ
requires_VPRT [SUAV]
goodwill_NN
to_TO
be_VB [PASS]
carried_VBN
at_PIN
cost_NN
with_PIN
impairment_NOMZ
reviews_NN
both_DT
annually_RB
and_PHC
also_RB
when_RB
there_EX
are_VPRT
indications_NOMZ
that_TOBJ
the_DT
carrying_VBG
value_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
Under_IN
the_DT
transitional_JJ
arrangements_NOMZ
of_PIN
IFRS_NN
1_CD
a_DT
company_NN
has_VPRT
the_DT
option_NOMZ
of_PIN
applying_VBG
IFRS_NN
3_CD
prospectively_RB
from_PIN
the_DT
transition_NOMZ
date_NN
to_PIN
IFRS_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
chosen_VBN
this_DEMO
option_NOMZ
rather_RB
than_PIN
to_TO
restate_VB
all_QUAN
previous_JJ
business_NOMZ
combinations_NOMZ
including_VBG [WZPRES]
accounting_GER
for_PIN
the_DT
merger_NN
of_PIN
Astra_NN
and_PHC
Zeneca_NN
._.
The_DT
impact_NN
of_PIN
IFRS_NN
3_CD
and_CC
associated_VBN
transitional_JJ
arrangements_NOMZ
on_PIN
AstraZeneca_NN
are_VPRT
as_IN
follows_VPRT
:_:
All_QUAN
prior_JJ
business_NOMZ
combination_NOMZ
accounting_GER
is_VPRT [PASS]
frozen_VBN
at_PIN
the_DT
transition_NOMZ
date_NN
._.
The_DT
value_NN
of_PIN
goodwill_NN
is_VPRT [PASS]
frozen_VBN
at_PIN
1_CD
January_NN
2003_CD
and_CC
amortisation_NOMZ
previously_TIME
reported_VBN [PUBV]
under_IN
UK_NN
GAAP_NN
for_PIN
2003_CD
and_CC
2004_CD
is_VPRT [PASS]
removed_VBN
._.
Dividends_NN
IAS_NN
10_CD
requires_VPRT [SUAV]
dividends_NN
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
a_DT
liability_NOMZ
when_RB
they_TPP3
are_VPRT [PASS]
declared_VBN [PUBV]
._.
For_PIN
the_DT
final_JJ
dividend_NN
this_DEMP
is_VPRT
usually_RB
after_IN
the_DT
accounting_GER
period_NN
to_PIN
which_WDT [PIRE]
it_PIT
relates_VPRT
,_,
when_RB
the_DT
dividend_NN
is_VPRT [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
._.
Consequently_CONJ
there_EX
is_VPRT
an_DT
adjustment_NOMZ
to_TO
remove_VB
the_DT
liability_NOMZ
for_PIN
the_DT
final_JJ
dividend_NN
declared_VBD [PUBV]
post_NN
year_NN
end_NN
._.
Capitalised_VBN
software_NN
and_CC
other_JJ
intangibles_NN
IAS_NN
38_CD
requires_VPRT [SUAV]
all_QUAN
intangible_JJ
assets_NN
that_TSUB
meet_VPRT
the_DT
capitalization_NOMZ
criteria_NN
to_TO
be_VB [PASS]
capitalized_VBN
._.
For_PIN
AstraZeneca_NN
,_,
this_DEMP
led_VBD
to_PIN
the_DT
following_VBG
Group_NN
policies_NN
being_VBG [WZPRES] [PASS]
applied_VBN
:_:
In_PIN
respect_NN
of_PIN
internal_JJ
product_NN
development_NOMZ
expenditure_NN
,_,
it_PIT
is_VPRT
managements_NOMZ
view_VPRT
that_DEMO
it_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
to_TO
demonstrate_VB [PRIV]
with_PIN
sufficient_JJ
certainty_NN
that_THVC
,_,
prior_RB
to_PIN
regulatory_JJ
approval_NN
,_,
these_DEMO
criteria_NN
are_VPRT [PASS]
met_VBN
._.
Consequently_CONJ
,_,
AstraZeneca_NN
would_PRMD
not_XX0
expect_VB [PRIV]
to_TO
capitalize_VB
internal_JJ
development_NOMZ
costs_NN
._.
In_PIN
respect_NN
of_PIN
internal_JJ
development_NOMZ
expenditure_NN
on_PIN
software_NN
,_,
it_PIT
is_VPRT
managements_NOMZ
view_VPRT
that_DEMO
some_QUAN
projects_NN
have_VPRT [PEAS]
met_VBN
the_DT
criteria_NN
for_PIN
capitalization_NOMZ
._.
Results_NN
have_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
to_TO
include_VB
both_DT
the_DT
capitalized_JJ
costs_NN
and_CC
associated_VBN
amortisation_NOMZ
of_PIN
these_DEMO
projects_NN
._.
The_DT
standard_JJ
requires_VPRT [SUAV]
all_QUAN
externally_RB
acquired_VBN
intangibles_NN
to_TO
be_VB [PASS]
capitalized_VBN
and_CC
the_DT
results_NN
have_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
to_TO
recognize_VB [PRIV]
a_DT
small_JJ
number_NN
of_PIN
products_NN
in_PIN
early_TIME
phase_NN
development_NOMZ
that_TSUB
had_VBD [PEAS]
been_VBN [PASS]
expensed_VBN
under_IN
UK_NN
GAAP_NN
._.
Deferred_JJ
taxation_NOMZ
IAS_NN
12_CD
requires_VPRT [SUAV]
deferred_JJ
tax_NN
to_TO
be_VB [PASS]
calculated_VBN [PRIV]
using_VBG
the_DT
purchasers_NN
tax_NN
rate_NN
instead_CONJ
of_NULL
the_DT
vendors_NN
tax_NN
rate_NN
under_IN
UK_NN
GAAP_NN
,_,
changing_VBG [PRESP]
the_DT
methodology_NN
used_VBN
to_TO
calculate_VB [PRIV]
deferred_JJ
tax_NN
on_PIN
unrealised_JJ
profit_NN
on_PIN
intra-group_JJ
sales_NN
._.
The_DT
standard_JJ
further_JJ
requires_VPRT [SUAV]
a_DT
deferred_JJ
tax_NN
provision_NN
for_PIN
all_QUAN
rolled_VBN
over_IN
capital_NN
gains_NN
rather_RB
than_PIN
those_DEMP
expected_VBN [PRIV]
to_PIN
crystallise_NN
._.
